Literature DB >> 16025511

APOBEC-mediated interference with hepadnavirus production.

Christine Rösler1, Josef Köck, Michael Kann, Michael H Malim, Hubert E Blum, Thomas F Baumert, Fritz von Weizsäcker.   

Abstract

APOBEC3G is a cellular cytidine deaminase displaying broad antiretroviral activity. Recently, it was shown that APOBEC3G can also suppress hepatitis B virus (HBV) production in human hepatoma cells. In the present study, we characterized the mechanisms of APOBEC-mediated antiviral activity against HBV and related hepadnaviruses. We show that human APOBEC3G blocks HBV production in mammalian and nonmammalian cells and is active against duck HBV as well. Early steps of viral morphogenesis, including RNA and protein synthesis, binding of pregenomic RNA to core protein, and self-assembly of viral core protein, were unaffected. However, APOBEC3G rendered HBV core protein-associated full-length pregenomic RNA nuclease-sensitive. Ongoing reverse-transcription in capsids that had escaped the block in morphogenesis was not significantly inhibited. The antiviral effect was not modulated by abrogating or enhancing expression of the accessory HBV X protein, suggesting that HBV X protein does not represent a functional homologue to the HIV vif protein. Furthermore, human APOBEC3F but not rat APOBEC1 inhibited HBV DNA production. Viral RNA and low-level DNA produced in the presence of APOBEC3F or rat APOBEC1 occasionally displayed mutations, but the majority of clones were wild-type. In conclusion, APOBEC3G and APOBEC3F but not rat APOBEC1 can downregulate the production of replication-competent hepadnaviral nucleocapsids. In contrast to HIV and other retroviruses, however, APOBEC3G/3F-mediated editing of nucleic acids does not seem to represent an effective innate defense mechanism for hepadnaviruses.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16025511     DOI: 10.1002/hep.20801

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  70 in total

1.  APOBEC3G and HIV-1: strike and counterstrike.

Authors:  Vanessa B Soros; Warner C Greene
Journal:  Curr Infect Dis Rep       Date:  2006-06       Impact factor: 3.725

Review 2.  Role and mechanism of action of the APOBEC3 family of antiretroviral resistance factors.

Authors:  Bryan R Cullen
Journal:  J Virol       Date:  2006-02       Impact factor: 5.103

3.  Cellular inhibitors of long interspersed element 1 and Alu retrotransposition.

Authors:  Hal P Bogerd; Heather L Wiegand; Amy E Hulme; José L Garcia-Perez; K Sue O'Shea; John V Moran; Bryan R Cullen
Journal:  Proc Natl Acad Sci U S A       Date:  2006-05-25       Impact factor: 11.205

4.  APOBEC3G and HIV-1: strike and counterstrike.

Authors:  Vanessa B Soros; Warner C Greene
Journal:  Curr HIV/AIDS Rep       Date:  2007-02       Impact factor: 5.071

Review 5.  Hepatitis B virus replication.

Authors:  Juergen Beck; Michael Nassal
Journal:  World J Gastroenterol       Date:  2007-01-07       Impact factor: 5.742

Review 6.  An overview of cytidine deaminases.

Authors:  Naveenan Navaratnam; Rizwan Sarwar
Journal:  Int J Hematol       Date:  2006-04       Impact factor: 2.490

Review 7.  Host restriction factors blocking retroviral replication.

Authors:  Daniel Wolf; Stephen P Goff
Journal:  Annu Rev Genet       Date:  2008       Impact factor: 16.830

Review 8.  The current structural and functional understanding of APOBEC deaminases.

Authors:  Ronda Bransteitter; Courtney Prochnow; Xiaojiang S Chen
Journal:  Cell Mol Life Sci       Date:  2009-06-23       Impact factor: 9.261

9.  Inhibition of hepatitis B virus replication by APOBEC3G in vitro and in vivo.

Authors:  Yan-Chang Lei; You-Hua Hao; Zheng-Mao Zhang; Yong-Jun Tian; Bao-Ju Wang; Yan Yang; Xi-Ping Zhao; Meng-Ji Lu; Fei-Li Gong; Dong-Liang Yang
Journal:  World J Gastroenterol       Date:  2006-07-28       Impact factor: 5.742

10.  Human APOBEC1 cytidine deaminase edits HBV DNA.

Authors:  Minerva Cervantes Gonzalez; Rodolphe Suspène; Michel Henry; Denise Guétard; Simon Wain-Hobson; Jean-Pierre Vartanian
Journal:  Retrovirology       Date:  2009-10-21       Impact factor: 4.602

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.